Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
Since ALT lacks a marketed drug in its portfolio, we do not expect it to record revenues. The Zacks Consensus Estimate for the bottom line is pegged at a loss of 32 cents per share.
Let's see how things might have shaped up before the announcement.
Factors Likely to Influence ALT's Q2 Results
Altimmune's lead pipeline candidate, pemvidutide, a novel, peptide-based GLP-1/glucagon dual receptor agonist, is currently being developed for treating obesity, metabolic dysfunction-associated steatohepatitis (MASH), alcohol liver disease (ALD) and alcohol use disorder (AUD).
Last month, the company announced top-line data from the phase IIb IMPACT study, which evaluated pemvidutide for treating MASH. The primary endpoints of the study were to achieve MASH resolution without a worsening of fibrosis and to improve fibrosis without a worsening of MASH.
In an intent-to-treat (ITT) analysis, at 24 weeks, MASH resolution without fibrosis worsening was achieved by 59.1% and 52.1% of participants receiving pemvidutide 1.2 mg and 1.8 mg, respectively, compared to 19.1% with placebo.
Meanwhile, in the ITT analysis, fibrosis improvement without MASH worsening was seen in 31.8% and 34.5% of participants receiving pemvidutide 1.2 mg and 1.8 mg, respectively, versus 25.9% with placebo. However, these differences were not statistically significant. Shares of the company tanked on this news.
Participants who received pemvidutide experienced an average weight loss of 5% with the 1.2 mg dose and 6.2% with the 1.8 mg dose, compared to 1% in the placebo group at 24 weeks. Treatment with pemvidutide was generally safe and well-tolerated.
Investors will be keen to get more updates on the development path ahead for pemvidutide on the upcoming earnings call.
Year to date, shares of Altimmune have plunged 43% against the industry's increase of 7.2%.
Altimmune recently initiated two separate phase II studies on pemvidutide for the treatment of AUD and ALD. Further updates on these studies are expected on the upcoming earnings call.
Operating expenses are most likely to have declined in the to-be-reported quarter due to the timing of clinical study costs.
ALT's Earnings Surprise History
Altimmune has a mixed earnings surprise history, beating estimates in three of the trailing four quarters and missing the same on the remaining occasion, the average surprise being 9.21%. In the last reported quarter, ALT posted an earnings surprise of 25.71%.
Altimmune, Inc. Price and EPS Surprise
What Our Model Predicts for ALT Stock
Our proven model does not conclusively predict an earnings beat for Altimmune this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
ALT's Earnings ESP: Altimmune has an Earnings ESP of 0.00% as both the Most Accurate Estimate and Zacks Consensus Estimate are pegged at a loss of 32 cents per share.
ALT's Zacks Rank: Altimmune has a Zacks Rank #3 at present. You can see the complete list of today's Zacks #1 Rank stocks here.
Stocks With the Favorable Combination
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Akero Therapeutics AKRO has an Earnings ESP of +0.53% and a Zacks Rank #1 at present.
AKRO stock has surged 81.5% year to date. Akero beat on earnings in three of the last four quarters and missed in the other one, delivering an average surprise of 48.90%.
Exact Sciences EXAS has an Earnings ESP of +475.00% and a Zacks Rank #2 at present.
Shares of EXAS have declined 13.5% year to date. EXAS beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 48.79%. Exact Sciences is scheduled to report second-quarter results on Aug. 6, after market close.
Alkermes ALKS has an Earnings ESP of +4.94% and a Zacks Rank #3 at present.
Shares of ALKS have lost 7.8% year to date. ALKS beat on earnings in one of the last four quarters and missed in the other three, delivering an average negative surprise of 8.24%. Alkermes will report second-quarter results on July 29, before market open.
#1 Semiconductor Stock to Buy (Not NVDA)
The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.
One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Altimmune, Inc. (ALT): Free Stock Analysis Report
Exact Sciences Corporation (EXAS): Free Stock Analysis Report
Akero Therapeutics, Inc. (AKRO): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
13 minutes ago
- Globe and Mail
US stock market holds steady after the Fed makes no move on interest rates
NEW YORK (AP) — U.S. stock indexes are drifting on Wednesday after the Federal Reserve decided to keep interest rates where they are, a move that could upset President Donald Trump but was one that Wall Street was widely expecting. The S&P 500 was edging up by 0.2% in afternoon trading, coming off its first loss after setting all-time highs for six successive days. The Dow Jones Industrial Average was up 25 points, or 0.1%, as of 2:05 p.m. Eastern time, and the Nasdaq composite was adding 0.4%. In the bond market, Treasury yields gave back some of their gains from the morning, when a report suggested the U.S. economy's growth was much stronger during the spring than economists expected. It grew at a 3% annual rate, according to an advance estimate, a full percentage point more than forecast. But underlying trends beneath the surface may be more discouraging. 'Cutting through the noise of the swings in imports, the economy is still chugging along, but it is showing signs of sputtering,' said Brian Jacobsen, chief economist at Annex Wealth Management. The data reinforced the dilemma facing Fed officials as they voted Wednesday on what to do with interest rates. They could have lowered rates, which would give a boost to the economy as Trump has so been angrily calling for. But lower rates could also give inflation more fuel when Trump's tariffs may be set to increase prices for U.S. households. Trump on Wednesday announced a 25% tariff on imports coming from India, along with an additional tax because of India's purchases of Russian oil, beginning on Aug. 1. That's when stiff tariffs Trump has proposed for many other countries are also scheduled to kick in, unless they reach trade deals that lower the rates. Fed Chair Jerome Powell has been insisting that he wants to see more data about how tariffs are affecting inflation and the economy before the central bank makes its next move, and he will speak shortly to offer more details about the decision. Two officials on the Fed's committee did dissent in Wednesday's vote, an indication that Powell may face increasing pressure to cut rates soon. Much of Wall Street expects the Fed to resume lowering rates in September. It's been on hold this year after cutting rates several times late last year. The yield on the two-year U.S. Treasury note edged up to 3.87% from 3.86% late Tuesday. It tends to closely follow expectations for what the Fed will do with its overnight interest rate. The 10-year Treasury, which also takes into account longer-term expectations for the economy and inflation, was holding at 4.34%. On Wall Street, stocks were mixed as most big U.S. companies continue to report profits for the spring that were bigger than analysts expected. Humana rose 10.3% after the insurer and health care giant reported stronger results for the spring than expected. It also raised its forecasts for profit and revenue over the full year. Video-game maker Electronic Arts climbed 7% after likewise topping Wall Street's expectations. The company said it saw better-than-expected contributions from EA Sports and other games, and it will reveal its new Battlefield game on Thursday. Companies are under pressure to deliver solid profit growth. They need to in order to justify the big jumps in their stock prices during recent months, which has caused some critics to say the broad U.S. stock market looks too expensive. Trane Technologies, whose stock came into the day with a 27.5% gain for the year so far, tumbled even though it reported a stronger-than-expected profit for the latest quarter. The heating, ventilation and air conditioning company's revenue came up short of analysts' estimates, as did its forecast for profit in the current quarter. It dropped 8%. Starbucks swung between gains and losses after it reported a weaker profit than analysts expected as it tries to turn around its operations. The company is hoping to boost its performance through improved store operations and new products, including a cold foam protein drink. Its stock was most recently up 0.4%. Palo Alto Networks fell 4.4% after saying it would buy CyberArk, an identity-security company, for $25 billion in cash and stock. CyberArk shares added 1.4%. In stock markets abroad, indexes were mixed across Europe and Asia. Hong Kong's Hang Seng fell 1.4%, and South Korea's Kospi rose 0.7% for two of the bigger moves.
Globe and Mail
13 minutes ago
- Globe and Mail
Xcel Energy Inc. Board Declares Dividend on Common Stock
The Board of Directors of Xcel Energy Inc. (NASDAQ: XEL) today declared a quarterly dividend on its common stock of 57 cents per share. The dividends are payable October 20, 2025, to shareholders of record on September 15, 2025. Xcel Energy is a major U.S. electricity and natural gas company, with operations in 8 Western and Midwestern states. Xcel Energy provides a comprehensive portfolio of energy-related products and services to 3.9 million electricity customers and 2.2 million natural gas customers through its regulated operating companies. Company headquarters are located in Minneapolis. More information is available at This information is not given in connection with any sale or offer for sale or offer to buy any securities. Statements in this press release regarding Xcel Energy's business which are not historical facts are 'forward-looking statements' that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see 'Risk Factors' in the Company's Annual Report on Form 10-K for the most recently ended fiscal year.
Globe and Mail
13 minutes ago
- Globe and Mail
NOW's Subscription Growth Picks Up: A Sign of More Upside?
ServiceNow 's NOW AI-powered platform is helping enterprises undergo business transformation by automating workflows across IT, customer service and business operations. NOW's cloud-based solutions streamline processes and improve productivity through intelligent automation. Growth in subscription revenues is the key driver of NOW's financial performance. In the second quarter of 2025, subscription revenues increased 22.5% year over year to $3.11 billion, surpassing the Zacks Consensus Estimates by 2.66%. Current Remaining Performance Obligations appreciated 21.5% year-over-year to $10.92 billion in the second quarter. ServiceNow secured 89 net new ACV deals over $1 million, including 11 above $5 million, implying strong enterprise demand during the reported quarter. Growth in NOW's subscription business is supported by rising adoption of its innovative product suite. AI-enhanced Pro Plus tiers of core products like ITSM, CSM and HRSD help customers automate workflows and accelerate resolution times. Tools such as Workflow Data Fabric and RaptorDB Pro unify data and support high-performance AI applications. In the reported quarter, the AI Pro Plus deal count increased by over 50% sequentially. ServiceNow also closed its largest Now Assist deal to date, exceeding $20 million, with 21 large transactions involving five or more Now Assist products. With strong adoption trends in place, ServiceNow expects 2025 subscription revenues of $12.785 billion and the Zacks Consensus Estimate for the same is pegged at $12.661 billion. As enterprises deepen platform adoption and expand across AI-driven SKUs, subscription growth is expected to remain the central engine for NOW's revenue expansion. NOW Faces Stiff Competition NOW faces stiff competition in the subscription-driven workflow automation space from the likes of Salesforce CRM and Pegasystems PEGA. Salesforce is benefiting from strong demand for its Einstein AI platform, which integrates across subscription offerings to enhance customer relationship management and automation capabilities. Salesforce has a steady subscription revenue growth driven by AI adoption. Salesforce recently expanded its subscription platform with advanced AI agents and workflow automation tools to compete directly with specialized automation providers like ServiceNow. Pegasystems remains a formidable competitor in the enterprise workflow subscription market, leveraging its GenAI Blueprint solution to accelerate application development. Pegasystems continues expanding its subscription-based platform with AI-powered decisioning capabilities, positioning it as a key rival for enterprise automation budgets in the growing subscription economy. NOW's Share Price Performance, Valuation and Estimates ServiceNow's shares have declined 6.3% year to date, underperforming the broader Zacks Computer & Technology sector's return of 11.4% but beating the Zacks Computer- IT services industry's decline of 9.9%. NOW Stock Performance Image Source: Zacks Investment Research ServiceNow stock is trading at a premium, with a forward 12-month Price/Sales of 14.19X compared with the sector's 6.72X. NOW has a Value Score of F. NOW Valuation The Zacks Consensus Estimate for ServiceNow's third-quarter 2025 earnings is pegged at $4.22 per share, which decreased by a penny over the past 30 days. This indicates a 13.44% increase year over year. ServiceNow, Inc. Price and Consensus The consensus mark for NOW's 2025 earnings is pegged at $16.79 per share, which has increased by 25cents over the past 30 days, suggesting 20.62% year-over-year growth. NOW currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. #1 Semiconductor Stock to Buy (Not NVDA) The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow. One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Salesforce Inc. (CRM): Free Stock Analysis Report ServiceNow, Inc. (NOW): Free Stock Analysis Report Pegasystems Inc. (PEGA): Free Stock Analysis Report
